Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Short-Term Debt issuances (2019 - 2020)

Zevra Therapeutics' Short-Term Debt issuances history spans 2 years, with the latest figure at $1.2 million for Q2 2020.

  • For Q2 2020, Short-Term Debt issuances fell 3.09% year-over-year to $1.2 million; the TTM value through Sep 2021 reached $1.2 million, down 48.28%, while the annual FY2020 figure was $2.3 million, 57.71% down from the prior year.
  • Short-Term Debt issuances reached $1.2 million in Q2 2020 per ZVRA's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $2.7 million in Q1 2019 to a low of $1.1 million in Q1 2020.